[Therapy for systemic urothelial cancer recurrence].
Detailed data on treating systemic recurrences of urothelial cancer after radical cystectomy and/or radical upper tract surgery are sparse. This review describes the data available from two large clinical phase III trials, one on systemic chemotherapy for metastatic/inoperable urothelial cancer and the other on adjuvant systemic chemotherapy after radical cystectomy for locally advanced bladder cancer. In addition, an overview of contemporary series on metastasectomy for urothelial cancer with palliative as well as curative intent is presented. The impact of therapeutic options for the treatment of systemic urothelial cancer recurrences such as radiotherapy, surgery or systemic first and second line therapy represented by conventional chemotherapy and contemporary target therapy are discussed.
Lehmann
J
J
Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg/Saar. jan.lehmann@uniklinikum-saarland.de
Stöckle
M
M
D000970:Antineoplastic Agents / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010166:Palliative Care / Q000379:methods*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents